<?xml version='1.0' encoding='utf-8'?>
<document id="25878331"><sentence text="Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma." /><sentence text="Aurora A kinase (AAK) is expressed exclusively during mitosis, and plays a critical role in centrosome duplication and spindle formation" /><sentence text=" Alisertib is a highly selective AAK inhibitor that has demonstrated marked clinical activity of alisertib across a spectrum of lymphomas, though particularly in patients with T-cell lymphoma (TCL)" /><sentence text=" We sought to compare and contrast the activity of alisertib in preclinical models of B-cell lymphoma (BCL) and TCL, and identify combinations worthy of clinical study" /><sentence text=" High-throughput screening of pralatrexate, the proteasome inhibitor (ixazomib), and the histone deacetylase (HDAC) inhibitor (romidepsin) revealed that only romidepsin synergized with alisertib, and only in models of TCL"><entity charOffset="30-42" id="DDI-PubMed.25878331.s5.e0" text="pralatrexate" /><entity charOffset="158-168" id="DDI-PubMed.25878331.s5.e1" text="romidepsin" /><entity charOffset="185-194" id="DDI-PubMed.25878331.s5.e2" text="alisertib" /><pair ddi="false" e1="DDI-PubMed.25878331.s5.e0" e2="DDI-PubMed.25878331.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25878331.s5.e0" e2="DDI-PubMed.25878331.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25878331.s5.e0" e2="DDI-PubMed.25878331.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25878331.s5.e1" e2="DDI-PubMed.25878331.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25878331.s5.e1" e2="DDI-PubMed.25878331.s5.e2" /></sentence><sentence text=" We discovered that the mechanism of synergy between AAK inhibitors and HDAC inhibitors appears to be mediated through cytokinesis failure" /><sentence text="" /><sentence text="A high-throughput screening approach was used to identify drugs that were potentially synergistic in combination with alisertib"><entity charOffset="118-127" id="DDI-PubMed.25878331.s8.e0" text="alisertib" /></sentence><sentence text=" Live-cell imaging was used to explore the mechanistic basis for the drug: drug interaction between alisertib and romidepsin"><entity charOffset="114-124" id="DDI-PubMed.25878331.s9.e0" text="romidepsin" /></sentence><sentence text=" An in vivo xenograft TCL model was used to confirm in vitro results" /><sentence text="" /><sentence text="In vitro, alisertib exhibited concentration-dependent cytotoxicity in BCL and TCL cell lines"><entity charOffset="10-19" id="DDI-PubMed.25878331.s12.e0" text="alisertib" /></sentence><sentence text=" Alisertib was synergistic with romidepsin in a T-cell-specific fashion that was confirmed in vivo"><entity charOffset="32-42" id="DDI-PubMed.25878331.s13.e0" text="romidepsin" /></sentence><sentence text=" Live-cell imaging demonstrated that the combination treatment resulted in profound cytokinesis failure" /><sentence text="" /><sentence text="These data strongly suggest that the combination of alisertib and romidepsin is highly synergistic in TCL through modulation of cytokinesis and merits clinical development"><entity charOffset="52-61" id="DDI-PubMed.25878331.s16.e0" text="alisertib" /><entity charOffset="66-76" id="DDI-PubMed.25878331.s16.e1" text="romidepsin" /><pair ddi="false" e1="DDI-PubMed.25878331.s16.e0" e2="DDI-PubMed.25878331.s16.e0" /><pair ddi="false" e1="DDI-PubMed.25878331.s16.e0" e2="DDI-PubMed.25878331.s16.e1" /></sentence><sentence text="" /></document>